Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Status of Cancer Clinical Trials
The Institute of Medicine of the National Academies reports that the state of cancer clinical trials in the U.S. has reached crisis mode. The study cites a number of factors responsible for this situation, such as too much bureaucracy, wasted funds, and lack of patient enrollment. Do you think that the Institute’s proposed goals of (1) improving the speed and efficiency of the design, launch, and conduct of clinical trials, (2) making optimal use of scientific innovations, (3) achieving better selection, prioritization, support, and completion of clinical trials, and (4) fostering expanded participation of both patients and physicians will effectively address the crisis in cancer clinical trials?